ArticleMovement disorders : official journal of the Movement Disorder Society2009
FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.
Article in Movement disorders : official journal of the Movement Disorder Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Quantitative assessment of the effect of FGF20 rs1721100 and rs12720208 variant on the risk of sporadic Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- Association between FGF20 rs12720208 gene polymorphism and Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Pooled it
- Quantitative assessment of the association between fibroblast growth factor 20 rs1721100 C/G polymorphism and the risk of sporadic Parkinson's diseases: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015Pooled it
- Fibroblast growth factor 20 (FGF20) gene polymorphism and risk of Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Pooled it
- A two-stage meta-analysis identifies several new loci for Parkinson's disease.PLoS genetics · 2011Pooled it
- FGF20 promotes spinal cord injury repair by inhibiting the formation of necrotic corpuscle P-MLKL/P-RIP1/P-RIP3 in neurons.Journal of cellular and molecular medicine · 2024Article
- Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes.Science translational medicine · 2021Article
- Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations.Brain : a journal of neurology · 2021Article
- Mechanisms by which fibroblast growth factor 20 improves motor performance in a mouse model of Parkinson's disease.Neural regeneration research · 2019Article
- Nucleic Acid-Based Therapeutics for Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Review
- MicroRNAs: Game Changers in the Regulation ofParkinson's disease · 2019Review
- microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.International journal of molecular sciences · 2017Review
- Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?Frontiers in aging neuroscience · 2017Review
- Epigenetic regulation in Parkinson's disease.Acta neuropathologica · 2016Review
- Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinson's disease.FEBS letters · 2015Article
- The best-laid plans go oft awry: synaptogenic growth factor signaling in neuropsychiatric disease.Frontiers in synaptic neuroscience · 2014Review
- Advances with microRNAs in Parkinson's disease research.Drug design, development and therapy · 2013Review
- Roles of FGF20 in dopaminergic neurons and Parkinson's disease.Frontiers in molecular neuroscience · 2013Article
- MicroRNAs in neurodegenerative diseases and their therapeutic potential.Pharmacology & therapeutics · 2012Review
- Parkinson's disease: leucine-rich repeat kinase 2 and autophagy, intimate enemies.Parkinson's disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 10 institutions in 4 countries.
Funding
Abstract
Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and alpha-synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient-control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and alpha-synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and alpha-synuclein protein levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.